2015 Diagnostic Cytopathology
January 17, 2015 to January 19, 2015

DoubleTree by Hilton Hotel and Suites (Historic District)
Charleston, SC, USA

This advanced course is designed to provide updated pragmatic, problem-solving knowledge for practicing surgical and cytopathologists who also wish to remain current with the changing trends in cytodiagnosis and laboratory management. It addresses the resolution of diagnostic pitfalls relative to each of the major organ systems studied by cytopathology/FNA and small biopsies. A syllabus containing the PowerPoint lecture material will be distributed at the course. Following the course, these PowerPoint lectures, as well as handouts and ancillary materials, will be available online for participants. Above all, this course is intended to provide a pleasant, informal atmosphere for learning, as well as opportunities for 1:1 interaction with the outstanding faculty.

 

The United States & Canadian Academy of Pathology (USCAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

The USCAP designates this live activity for a maximum of 18.25 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

The USCAP is committed to assisting its members with meeting their American Board of Pathology (ABP) Maintenance of Certification (MOC) requirements for Self-Assessment Modules (SAMs) credits.  Participants in the 2015 Diagnostic Cytopathology Course may earn 17.25 SAMs credits.

 

After attending the Diagnostic Cytopathology Course, participants should be better able to:

 

  • Triage cytologic specimens for preliminary and final interpretations for a variety of body sites with an understanding of cytologic limitations and managerial impact.
  • Utilize appropriate nomenclature for thyroid, pancreas, gynecologic, lung, lymph nodes, and urine cytology.
  • Understand advantages and pitfalls in commonly used and new molecular tests and immunohistochemical stains utilizing cytologic specimens and small biopsies, particularly in thyroid, urine, breast, lymph nodes and lung.
  • Discuss genomics as it pertains to small samples and to know which tests are becoming standard of care and which are still in discovery and validation phase.
  • Ascertain the current guidelines and consensus for Pap tests, cervical/endocervical biopsies, HPV testing and management.